Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Anterior cingulate serotonin 1B receptor binding is associated with emotional response inhibition

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hippocampal volume changes in healthy subjects at risk of unipolar depression

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hot and cold cognitive disturbances in antidepressant-free patients with major depressive disorder: a NeuroPharm study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Structural brain abnormalities associated with cognitive impairments in bipolar disorder

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Parkinson patients have a presynaptic serotonergic deficit: A dynamic deep brain stimulation PET study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

While several electroencephalogram (EEG)-based biomarkers have been proposed as diagnostic or predictive tools in major depressive disorder (MDD), there is a clear lack of replication studies in this field. Markers that link clinical features such as disturbed wakefulness regulation in MDD with neurophysiological patterns are particularly promising candidates for e.g., EEG-informed choices of antidepressive treatment. We investigate if we in an independent MDD sample can replicate abnormal findings of EEG-vigilance regulation during rest and as a predictor for antidepressive treatment response. EEG-resting state was recorded in 91 patients and 35 healthy controls from the NeuroPharm trial. EEG-vigilance was assessed using the Vigilance Algorithm Leipzig (VIGALL). We compared the vigilance regulation during rest between patients and healthy controls and between remitters/responders and non-remitters/non-responders after eight weeks of SSRI/SNRI treatment using two different sets of response criteria (NeuroPharm and iSPOT-D). We replicated previous findings showing hyperstable EEG-wakefulness regulation in patients in comparison to healthy subjects. Responders defined by the iSPOT-D criteria showed a higher propensity toward low vigilance stages in comparison to patients with no response at pretreatment, however, this did not apply when using the NeuroPharm criteria. EEG-wakefulness regulation patterns normalized toward patterns of healthy controls after 8 weeks of treatment. This replication study supports the diagnostic value of EEG-vigilance regulation and its usefulness as a biomarker for the choice of treatment in MDD.

Original languageEnglish
JournalJournal of Psychiatric Research
Volume141
Pages (from-to)57-65
Number of pages9
ISSN0022-3956
DOIs
Publication statusPublished - Sep 2021

    Research areas

  • Arousal, Biomarkers, Depressive Disorder, Major/drug therapy, Electroencephalography, Humans, Wakefulness, SSRI, Biomarker, EEG, Antidepressant treatment effect, VIGALL, MDD

ID: 67559868